Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
Open Access
- 29 September 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (15), 1547-1555
- https://doi.org/10.1016/s1470-2045(15)00207-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Ponatinib in Refractory Philadelphia Chromosome-Positive LeukemiasThe New England Journal of Medicine, 2012
- Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?Transplantation and Cellular Therapy, 2011
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitorsCancer, 2008
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateBlood, 2004
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001